Introduction {#Sec1}
============

Colon and rectal cancers (colorectal cancer, CRC) represent globally, in terms of frequency, the third leading cause of cancer-related mortality (ie, after lung and breast cancer). Nevertheless, CRC incidence and mortality rates vary over 10-fold worldwide. Lowest incidence rates are observed in Africa and Asia and highest ones are found in Australia/New Zealand, North America, and Western Europe with a mortality rate of approximately 30%. Although incidence rates in developed countries are stabilizing, they are severely increasing in both developing countries and several areas historically at low risk \[[@CR1]\]. Since the 1970s, CRC incidence in USA has continuously increased in the African-American population to become more frequent in this population than in Caucasians or other ethnic groups \[[@CR2]\]. Similarly, data from migration population studies revealed that some ethnic groups are showing increased CRC incidence rate while they are migrating from low-risk to high-risk areas, to finally reach rates comparable to the host country \[[@CR3]--[@CR5]\]. Despite genetic variation, these epidemiological data strongly suggest a role of environmental and lifestyle factors deeply contributing to the etiology of CRC.

Although it is well accepted that genetic factors and inflammatory bowel disease place certain individuals at increased risk \[[@CR6]\], various modifiable lifestyle factors have been identified related to CRC pathogenesis. Significant lifestyle risk factors are represented by sedentarity and changes in dietary habits, from a moderate to a Western-like enriched diet associated with high consumption of unsaturated fats and red meat, high intake of alcohol, and smoking.

Epigenetic mechanisms are fundamental to tightly regulated cellular processes. Epigenetic aberrations governing tumor suppressor gene (TSG) inactivation, oncogene activation, and chromosomal instability play a fundamental role in tumorigenesis including CRC. Epigenetic events are involved in all critical pathways and steps of carcinogenesis including tumor initiation, and some events are usually detectable before neoplastic transformation \[[@CR7], [@CR8], [@CR9]•, [@CR10]\]. Nonetheless, it is well accepted that environmental and dietary factors greatly influence epigenetic events. Moreover, the reversibility of epigenetic alterations stimulates the development of novel therapeutic approaches with an open field for development in cancer chemoprevention. Taking together, these observations suggest that improved early detection and dietary intervention are preventive approaches of choice to decrease CRC incidence.

In this review, we focus on epigenetic alterations associated with CRC, which offer promising novel biomarkers for early detection, with an emphasis on how these alterations can potentially be modulated by dietary compounds for preventive interventions.

Colorectal Carcinogenesis and Cancer Prevention {#Sec2}
===============================================

The vast majority of CRCs are a multistep-associated adenoma-carcinoma progression associated with successive clinico-histopathological stages. This transformation initially starts with a premalignant lesion, called aberrant crypt foci (ACF), rising from normal colonic mucosa, progressing to a premalignant lesion (ie, adenoma), and finally evolving to invasive adenocarcinoma and metastasis (Fig. [1](#Fig1){ref-type="fig"}). The tumor-node-metastasis (TNM) system stages CRCs depending on the extent of invasion of the intestinal wall (T), the degree of lymphatic node involvement (N), and whether there is presence of metastasis (M). Based on this system, CRC is ranked from 0 (in situ tumor confined to mucosa) to stage IV (presence of metastasis). Thus, an increasing ranking correlates to a more advanced cancer and likely a worse outcome \[[@CR11]\].Fig. 1Colorectal cancer (CRC) progression as a model for epigenetic alteration cascade and prevention strategies. CRC development is initially starting by a premalignant lesion, called aberrant crypt foci (ACF), rising from normal colonic mucosa, progressing to a premalignant lesion (adenoma) and then to invasive adenocarcinoma, and finally evolving to metastatic adenocarcinoma. Epigenetic alterations are largely contributing to CRC initiation and adenoma-carcinoma progression. These alterations are characterized by global genomic DNA hypomethylation leading to genomic instability and oncogene activation concomitantly to an increase of CpG island promoter hypermethylation-mediated silencing of tumor suppressor genes. These changes are accompanied by an increase of aberrant histone modification profiles and miRNA signatures reinforcing oncogenic activation and tumor suppressor loss associated with CRC progression. Consequently, epigenetic alterations represent promising targets for CRC prevention. Early epigenetic aberrations represent interesting targets for primary prevention, especially through chemoprevention by dietary epigenetic modulators, as well as for secondary prevention as early biomarkers of CRC initiation. Modifications occurring at later stages may be targeted by chemotherapeutic interventions as well as chemopreventive agents to limit or block disease progression (secondary and tertiary prevention activities)

Although most CRCs occur sporadically, the importance of inheritance associated with a family history of the disease is evaluated to approximately 25% \[[@CR12]\]. Some well-defined syndromes associated with CRC pathobiology have been identified: hereditary non-polyposis CRC (HNPCC), familial adenomatous polyposis (FAP), and MUTYH-associated polyposis (MAP), which are caused by germline mutations in DNA mismatch repair (MMR) genes, adenomatous polyposis coli (APC) TSG, and MUTYH gene, respectively; plus a number of relatively rare polyposis syndromes \[[@CR13]\].

Mechanisms underlying the adenoma-carcinoma sequence have been identified for their contribution to CRC pathogenesis in relation to alterations of TSG and oncogene functions. Among these mechanisms, genomic instability represented by two "genotypic" subtypes pathways associated with somatic mutations are frequently identified: chromosomal instability (CIN) and microsatellite instability (MSI) \[[@CR9]•, [@CR13]\]. Although CIN is observed in approximately 85% of CRC cases, the initiating mechanism is still poorly understood. The most common cytogenic abnormalities observed in CIN are mutations of APC gene, which occur in the majority of sporadic CRCs and also very early in adenoma development, and chromosome aberrations such as loss of heterozygosity of 5, 17p, and 18q. The latter contains the deleted in colorectal cancer (DCC) TSG. MSI is characterized by the inactivation of genes implicated in mismatch repair (MMR) system leading to subsequent mutations in the microsatellite repeat sequences of genes linked to tumor progression \[[@CR13]\]. In addition to somatic mutations, epigenetic alterations are also particularly common in CRC. Epigenetics is defined as the heritable changes in gene expression patterns that occur without a change in the primary DNA sequence. This field encompasses DNA methylation, histone modifications and chromatin remodeling, and non-coding RNA-mediated interference \[[@CR9]•, [@CR10], [@CR13]\].

After years of research it appears that the best way to avoid the burden of cancer might be prevention. Under the general concept of prevention, several levels of approaches are encompassed \[[@CR14]\]. Avoiding exposure to potential carcinogens or life risk factors is associated with the primary level of prevention. However, preemptive behavior prevention is not limited to this aspect. Indeed, chemoprevention, ie*,* the use of natural agents in healthy individuals without signs of premalignancy, falls also in this category. Secondary prevention corresponds to early detection of tumor-related abnormal changes aiming to prevent cancer development. Screening tests are included in this category, which require robust clinical biomarkers for early diagnosis. Finally, tertiary prevention consists to control cancer development to a more advanced-stage or reoccurrence after treatment and reduce adverse health effects.

Given the fact that epimutations are potentially reversible, the major field of applications regarding epigenetics might be cancer prevention. Accordingly, epimutations represent secondary prevention biomarkers by their precocity in carcinogenesis processes (ie, before neoplastic transformation). Primary to tertiary prevention may be achieved through chemoprevention, with dietary agents controlling epigenetic (re)programming, to either prevent or reverse premalignant stem cell phenotypes (Fig. [1](#Fig1){ref-type="fig"}).

Epimutations in CRC: Biomarkers and Targets for Prevention {#Sec3}
==========================================================

DNA Methylation in CRC {#Sec4}
----------------------

In humans, DNA methylation occurs at the 5′ position of the pyrimidine ring of the cytosine residues within CpG dinucleotides through addition of a methyl moiety to form 5-methylcytosines. This process is catalyzed by three DNA methyltransferases (DNMT1, DNMT3A, and DNMT3B) using the cofactor *S*-adenosyl-methionine (SAM). Although CpG dinucleotides represent approximately 1% of the human genome, they are unequally distributed across the genome and are clustered in small DNA stretches. These CpG-rich regions, called CpG islands (CGIs), are usually present near promoters and exogenic regions. CGIs are usually unmethylated in normal differentiated cells, whereas CpGs located in intergenic regions are methylated \[[@CR8], [@CR15]\].

In cancer, promoter CGI of numerous TSGs are found to be densely methylated, which results in transcriptional silencing. Interestingly, these epimutations may be cancer type-specific and tumor stage-specific. Thus, methylation patterns can be considered as biomarkers for diagnosis, prognosis, as well as prediction and monitoring of therapy response \[[@CR8], [@CR10], [@CR15], [@CR16]\]. Therefore, the identification of these cancer-associated methylation signatures is really critical for cancer prevention purposes.

Recent studies show that CRC is strongly associated with aberrant DNA methylation profiles, which has been linked to the origin and progression of the disease. The list of epimutations is growing quickly with the use of developing technologies allowing genome studies. To date, a long list of TSGs involved in numerous signalization pathways and cellular processes were found frequently methylated in CRC (Table [1](#Tab1){ref-type="table"}). Noteworthy, a widespread contribution of DNA methylation participates in the disruption of β-catenin--dependent Wnt signaling pathway, which plays an important role in colorectal tumor development \[[@CR9]•, [@CR13]\]. Moreover, methylation can affect coding and non-coding genes (eg, microRNA, miRNA) participating in loss of tumor suppressor functions. Remarkably, most of these methylated genes are investigated as potential biomarkers for preventive or therapeutic purposes. However, the methylation prevalence varies substantively depending on the considered genes as well as between studies regarding a same gene. The discrepancy between studies, like the case of CDKN2A (p16), for which methylation ranged from 10% to 58% depending on reports \[[@CR17]--[@CR19]\], could be explained by the phenotype of patients constituting these cohorts as well as how clinical parameters were included in these analyses. Indeed, certain genes are found frequently methylated in specific CRC subgroups, such as AXIN2 found preferentially associated with MSI tumors \[[@CR20]\].Table 1Epimutations associated with colorectal cancer based on experimental data from patients^a^Epigenetic eventNameLocusFunction/targetsNote^b^CommentsHypermethylationADAMTS521q22.1-q22ProteaseNAIncrease of methylation level in CRCADHFE18q12.3Alcohol dehydrogenaseNAIncrease of methylation level in CRCALX411p11.2Homeobox gene85/64Adenoma vs CRCAPBA19q13-q21Intracellular signaling16--28APBA215q11-q12Intracellular signaling22/26Stage I + III vs IVAPC5q22.2Wnt signaling21APC219p13.3Wnt signaling100AXIN217q24.1Wnt signaling29Associated with MSI tumorsB4GALNT112q13.3Lipid metabolism100B4GALNT217q21.3Lipid metabolism50Correlated with EBV-associated gastric carcinomasBARX19q12Homeobox gene56BMP34q21.21Bone and cartilage formation72/60Adenoma vs CRCBNIP310q26.3Apoptosis66BOLL2q33.1DevelopmentNAIncrease of methylation level in CRCCACNA1G17q22Calcium metabolism39CASR3q21.1Calcium metabolism9/69/90Adenoma vs CRC vs lymph node metastatic tissuesCCNA113q13.3Cell cycle100CD1096q13Complement system33CDH116q22.1Cell adhesion51CDH1316q23.3Cell adhesion32--66Poor prognosisCDH218q12.1Cell adhesion45CDH420q13.3Cell adhesion78CDKN2A (p14)9p21.3Cell cycle34CDKN2A (p16)9p21.3Cell cycle10--58CDKN2B (p15)9p21.3Cell cycle68CDX15q33.1Homeobox gene100CHFR12q24.33Cell cycle26--63Associated with disease recurrenceCNRIP12p14G protein-coupled receptor91/94Adenoma vs CRCCNTFR9p13.3Cytokine signaling22CPAMD819p13.12Innate immunity90CXCL1210q11.21Cytokine signaling62DAPK19q21.33Apoptosis43DCC18q21.2Putative TSG81/83Adenoma vs CRC (20% in normal)DFNA57p15.3Unknown65DKK110q21.1Wnt signaling13--35Associated with MSI tumorsDKK24q25Wnt signaling65DKK311p15.3Wnt signaling35DKK48p11.2-p11.1Wnt signaling20DLC1-i48p22Putative TSG100DLEC13p22.2Putative TSG38Poor prognosisEFEMP12p16.1Cell migration39Poor prognosisEGFR7p11.2Cytokine signaling58Poor prognosisEN12q13-q21Homeobox gene33EphA17q32-q34Intercellular signaling49Poor prognosisEphA54q13.1Intercellular signaling53EphA76q16.1Intercellular signaling49More frequent in moderately differentiated adenocarcinomasEPHB21p36.12Intercellular signaling53ESR16q25.1Hormonal signaling31EVL14q32.32Cell migration60EYA220q13.1Development44/51Adenoma vs CRCEYA46q23Development70FAM127AXq26Unknown58FBN115q21.1ECM component69/79Adenoma vs CRCFBN25q23.3ECM component90FLNC7q32.1Cell migration30FOXL23q23Transcription factor50GAS717p13.1DevelopmentNAIncrease of methylation level in CRCGATA48p23.1Transcription factor70Independent of clinicopathologic featuresGATA520q13.33Transcription factor79Independent of clinicopathologic featuresGPNMB7p15Development100GPR101Xq25-q27.1G protein-coupled receptor40GRID110q22Glutamate receptor60GRIN2A16p13.2Glutamate receptor82GSPT2Xp11.22GTPase21GUCY1A211q21-q22Intercellular signaling50HACE16q16.3Stress response28HIC117p13.3Transcriptional repressor35/42Adenoma vs CRCHLTF3q24Transcription factor18--34HOXB1317q21.32Homeobox gene40HRK12q24.23Apoptosis36HUS17p12.3Cell cycle22ID46p22.3Transcription factor46IGF211p15.5Development22IGFBP37p12.3Hormonal signaling25IGFBP74q12Hormonal signaling18/23Adenoma vs CRCIKZF17p12.2Transcriptional activator30--82% increase with Duke's stagesINA10q24.33Development35/65Adenoma vs CRCINHBB2q14.2Inhibin30IRF816q24.1Transcription factor43ITGA42q31.3Cell adhesion75/92Adenoma vs CRCKCNK122p16.3Potential potassium channel41KLF49q31.2Transcription factor25LAMA118p11.31Cell migration100LRRC3B3p24.1Putative TSG77MAL2q11.1Proteolipids84/91Adenoma vs CRCMGMT10q26.3DNA repair20--60miR-1-120q13.33Translational repression50miR-9-11q22Translational repression50Associated with the presence of lymph node metastasismiR-34a1p36.22Translational repression74miR-34b/c11q23.1Translational repression99miR-124-18p23.1Translational repression75miR-129-211p11.2Translational repression83miR-1371p21.3Translational repression100miR-148NATranslational repression65miR-34214q32.2Translational repression67/86Adenoma vs CRCmiR-34514q32.2Translational repression87miR-37319q13.42Translational repression88MLH13p22.2DNA repair18--22Poor prognosisMMP216q12.2Protease95MYOD111p15.1Transcription factor69NDRG214q11.2Putative TSG27NDRG416q21Putative TSG70--86NEURL10q25.1Putative TSG31NEUROG15q31.1Putative TSG36NPY7p15.1Putative TSGNAIncrease of methylation level in CRCNRCAM7q31.1Cell adhesion50NTNG11p13.3Development70NTRK29q21.33Differentiation100OSMR5p13.1Cytokine signaling55/89/90Mucosa adjacent to CRC vs colorectal polyps vs carcinomaPAPSS210q23.2Development100PDLIM45q31.1Development85/70Adenoma vs CRCPPM1E17q23.2Phosphatase55PRKD114q12Kinase20PROM14p15.32Putative TSG62PTGIS20q13.1-q13.3Prostaglandin signaling30/44Adenoma vs CRCPTGS21p25.2-3Inflammation72PTPRD9p23Phosphatase50RAB326q24.3Ras signaling56MSI tumorsRARβ3p24.2Hormonal signaling33--85RASSF1A3p21.2Ras signaling41/57Stage I/III vs IVRASSF220p13Ras signaling42RASSF51q32.1Ras signalingNAIncrease of methylation level in CRCRECK9p13.3Putative TSG44RUNX31p36.11Transcription factor27--63Poor prognosisSCTR2q14.1G protein-coupled receptor81SFRP18p11.21Wnt signaling95--100SFRP47p14.1Wnt signaling100SH3TC14p16.1Putative TSG40SLC5A812q23.1Solute carrier80SLC6A1512q21.31Solute carrierNAIncrease of methylation level in CRCSLIT24p15.2Cell migration72SMO7q32.1G protein-coupled receptor21SNCA4q21.3-q22Dopamine signaling53/66Adenoma vs CRCSOCS116p13.13Cytokine signaling22SOX178q11.23Transcription factor86/89--100Adenoma vs CRCSPARC5q33.1ECM component100SPG2013q13.3Putative TSG78/89Adenoma vs CRCSST3q28Hormonal signaling90ST3GAL63q12.2Putative TSG44Correlated with EBV-associated gastric carcinomasSTARD8Xq13.1Putative TSG55SYNE16q25.2Putative TSG95SYT61p13.2Calcium metabolism64TAC17q21.3Hormonal signaling95TCERG1L10q26.3Putative TSG100TFPI27q22ECM componentNAIncrease of methylation level in CRCTIMP322q12--13ECM component23TMEFF22q32.3-q33Cell proliferation77TP731p36.33Cell cycle control (G1-S)63TUBG217q21Cell migration71TUSC38p22Putative TSG66Associated with ulcerative colitisTWIST17p21.1Transcription factorNAIncrease of methylation level in CRCUNC5C4q22.3Development64/76Adenoma vs CRCVIM10p13Cell migration91/77Adenoma vs CRCWIF-112q13.13WIF-1100Very limited number of samplesWNT5a3p14.3Wnt signaling20Associated with MSI and BRAF V600E mutationWRN8p12DNA repair29WT111p13Transcription factor58ZNF56919q13.12Transcription factor40HypomethylationC7orf507p22.3UnknownNACARD1417q25.3NF-κB signalingNACCDC11622q11.21Transcriptional regulatorNACDH316q22.1Cell adhesion77CSRP11q32.1DevelopmentNAEPHX41p22.1Cell detoxificationNAGPR109A12q24.31G protein-coupled receptorNAGPSM19q34.3G protein signalingNAGRAP17p11.2Intracellular signalingNAH1911p15.5Putative TSG18HIST1H2BO6p22.1HistoneNAIGF211p15.5Development35Poor prognosisL1CAMXq28Cell adhesionNALAMB17q22ECM componentNALILRA419q13.4Cytokine signalingNALINE1NARetrotransposonNAAssociated with MSI and CIMP tumorsMAEL1q24.1piRNA systemNAMIRLET7BHG22q13.31Long non-coding RNANANRXN12p16.3Cell adhesionNANUP5022q13.3Macromolecule traffickingNAS100A41q21.3Cell cycleNAS1PR419p13.3G protein-coupled receptorNASFT2D32q14.3Transport and traffickingNASLC39A48q24.3Solute carrierNASLC6A185p15.33Solute carrierNASLC6A63p25.1Solute carrierNATIAM121q22.1Cell migrationNAAssociated with metastasismiRNAlet-7 familyNADLD-1, c-Myc, K-RAS−Poor prognosismiR-1-120q13.33TAGLN2−miR-9-11q22−miR-10b2q31.1−miR-15b3q25.33+miR-16NAWip1−miR-1713q31.3E2F1+Poor prognosis, MSS tumorsmiR-18a13q31.3K-RAS+Without lymph node metastasismiR-18bXq26.2+Without lymph node metastasismiR-19a13q31.3PTEN+Without lymph node metastasismiR-19bNA+miR-20a13q31.3BNIP2+MSImiR-2117q23.1Cdc25A, MSH2, PTEN, RECK, TIMP3+Poor prognosis, decrease of chemotherapy response, MSI tumorsmir-24NADHFR−miR-257q22.1+miR-26b2q35EphA2−miR-29a7q32.3+miR-29bNA+miR-30a6q13Beclin 1−miR-30cNA−miR-319p21.3FIH-1+Poor prognosismiR-329q31.3+miR-33a22q13.2+miR-34a1p36.22Bcl2, CDK4/6, E2F3, MET, SIRT1−miR-34b/c11q23.1Tp53−miR-92aNA+MSS tumorsmiR-937q22.1+miR-954SNX1+miR-967q32.2+miR-99a21q21.1−miR-101NACOX-2−MSI tumorsmiR-106aXq26.2E2F1+miR-106b7q22.1CDKN1A (p21)+Without lymph node metastasismiR-124-18p23.1−miR-125a19q13.41−miR-125bNA+Poor prognosismiR-1269q34.3p85β−Associated with metastasismiR-12714q32.2−miR-129-211p11.2−miR-103bNA+miR-133aNA−miR-133b6p12.2c-Met+miR-135aNAAPC+miR-135b1q32.1APC+Without lymph node metastasismiR-1371p21.3Cdc42, LSD-1−miR-13911q13.4β--Catenin−miR-14016q22.1HDAC4−miR-14112p13.31TGF-β1+miR-14217q22−MSS tumorsmiR-1435q32DNMT3A, Erk5, K-RAS−Decrease of chemotherapy response, associated with metastasismiR-1455q32FLI1, IRS1, STAT1, YES−MSI tumorsmiR-146b10q24.32−MSS tumorsmiR-15521q21.3MLH1, MSH2, MSH6+With lymph node metastasismiR-181bNA+Decrease of chemotherapy responsemiR-1827q32.2+miR-1837q32.2Klf4, Sox2, BMI1+miR-1913p21.31−miR-19211q13.1DHFR, TS, TYMS−Decrease of chemotherapy responsemiR-19517p13.1Bcl-2−mir-196aNAAKT−Increase metastasis potentialmir-196b7p15.2+Without lymph node metastasismiR-200a1p36.33ZEB1, ZEB2, MLH1, MSH2+Associated with metastasismiR-200b1p36.33MLH1, MSH2+Associated with metastasismiR-200c12p13.31TGF-β2, ZEB1, ZEB2, BMI1, PTPN12+Poor prognosis, associated with metastasismiR-20314q32.33Klf4, Sox2, BMI1+miR-21217p13.3−MSSmiR-2151q41DHFR, TS, TYMS−Decrease of chemotherapy responsemiR-2172p16.1−MSSmiR-223Xq12+miR-224Xq28+Without lymph node metastasismiR-301b22q11.21+Without lymph node metastasismiR-3208p21.3−Poor prognosismiR-32816q22.1−miR-3357q32.2+Without lymph node metastasismiR-34214q32.2DNMT1−miR-34514q32.2BAG3−miR-37319q13.42LATS2, CD44, RAB22A−miR-374aXq13.2+Without lymph node metastasismiR-3785q32−Without lymph node metastasismiR-378\*5q32−Without lymph node metastasismiR-422a15q22.31−miR-424Xq26.3+Without lymph node metastasismiR-432\*14q32.2+MSI tumorsmiR-45117q11.2MIF−Poor prognosismiR-4559q32−MSI tumorsmiR-48416p13.11−MSI tumorsmiR-4868p11.21−miR-49212q22+MSI tumorsmiR-49717p13.1−miR-49819q13.42−Poor prognosismiR-510Xq27.3+MSS tumorsmiR-513NA+MSS tumorsmiR-542Xq26.3+miR-5521p34.3+miR-5927q31.33+MSS tumorsmiR-67511p15.5Rb+CIMP, CpG island methylator phenotype; ECM, extracellular matrix; MSI, microsatellite instability; MSS, microsatellite stable; TSG, tumor suppressor gene.^a^Only hypermethylated genes with methylation prevalence ≥ 20% in CRC patients and ≤ 10% in normal mucosa were reported. Gene symbols and chromosome location are in accordance with [www.genecards.org.](http://www.genecards.org.)^b^For DNA hypermethylation/hypomethylation, number represent prevalence (%) in CRC; for miRNAs, - and + mean down-regulated and up-regulated in CRC compared to normal mucosa, respectively; NA means "not applicable."

Besides its diagnostic potential, methylated genes are associated with a number of clinical features correlated with poor prognosis (DLEC1, EFEMP1, EphA1, EGFR, MLH1, CDH13) \[[@CR19], [@CR21]--[@CR24]\], Epstein-Barr virus--associated gastric carcinomas (B4GALNT2, ST3GAL6) \[[@CR25]\]. In contrast, some methylated genes (GATA4, GATA5) are found methylated independently of clinicopathologic features \[[@CR26]\].

Some genes are not, at least alone, good biomarkers for CRC since they are frequently methylated in other cancer types such CDKN2A (p16), found methylated across various tumors \[[@CR10], [@CR16]\]. In contrast, APC2, B4GALNT1, CCNA1, CDX1, GPNMB, LAMA1, NTRK2, PAPSS2, TCERG1L, and SFRP4 genes are found methylated near 100% of patients tested \[[@CR19], [@CR27]--[@CR29]\]. Therefore, these genes could represent promising CRC biomarkers, similarly to the methylation of detoxification enzyme GSTP1, which is a hallmark of prostate cancer, even though data suggest it may also occur in other cancers \[[@CR16], [@CR30]\]. Nevertheless, it confirms that epigenetic silencing is far more common than mutations (see for review of mutation frequencies \[[@CR13]\]). Interestingly, numerous genes are gradually methylated during colorectal carcinogenesis. By example, CASR is found methylated at 9%, 69%, and 90% in adenoma, carcinoma, and lymph node metastatic tissues, respectively \[[@CR31]\]. Intriguingly, some CRC patients accumulate methylation abnormalities in a large number of genes. This CRC subset is defined with CpG island methylator (CIMP) phenotype characterized by clinicopathological and genetic (chromosomal instability) features, which are the consequence of hypermethylation-mediated TSG silencing involved in the malignant transformation of colonic tissue \[[@CR32]\]. In sporadic MSI tumors, hypermethylation-mediated silencing of MMR genes such as MLH1 is common \[[@CR19], [@CR23], [@CR24]\].

Concomitant with DNA promoter CGI hypermethylation-mediated silencing, global genomic hypomethylation is observed in CRC. This hypomethylation is usually associated with oncogene activation and genetic instability. Accordingly, an increasing list of genes were identified as hypomethylated in CRC patients, such as CCDC116, SFT2D3, MAEL, and H19/IGF2, which could also be used as biomarkers to reinforce CRC detection \[[@CR33]••, [@CR34]\]. Furthermore, a recent study suggests that long interspersed nuclear element-1 (LINE-1) hypomethylation could be used as a predictive biomarker of chemotherapy response to fluoropyrimidines in CRC patients \[[@CR35]\].

Finally, DNMT expression might also be used as a marker, since overexpression of DNMT1 mRNA was reported in 42% of CRC \[[@CR36]\].

All together, these events may represent powerful biomarkers for secondary prevention and risk stratification in CRC. Accordingly, these markers represent promising targets for therapeutic/chemopreventive interventions.

miRNA in CRC {#Sec5}
------------

MiRNA pathway is an additional epigenetic mechanism implicated in the regulation of tightly regulated biological processes. MiRNAs are endogenous short non-coding RNAs (\~22 nucleotides) that post-transcriptionally regulate mRNA expression levels in a sequence-specific manner. MiRNAs bind sequences located essentially in 5′ and 3′ untranslated regions of target genes degrading mRNA or blocking translation. Increasing amount of evidence reveals that miRNA expression signature dysregulations are associated with carcinogenesis, suggesting miRNAs might act as a novel class of oncogenes or TSGs \[[@CR8], [@CR10], [@CR37]\].

An increasing number of reports indicate that miRNA dysregulations are important in colorectal carcinogenesis. Table [1](#Tab1){ref-type="table"} summarizes these alterations based on experimental data from patients. MiRNome signatures revealed that miRNA affected many tumor-suppressive and oncogenic pathways implicated in CRC pathobiology, including β-catenin/Wnt signaling (miR-135a, -135b, -139, -145) \[[@CR38]•, [@CR39], [@CR40]\], apoptosis (miR-34a, -133b, -195) \[[@CR38]•, [@CR41]\], differentiation (miR-141, -200c) \[[@CR42]--[@CR44]\], p53 signaling (miR-34b/c) \[[@CR45]\], proliferation (K-RAS signaling: let7 family, miR-18a, -143, -200c) \[[@CR38]•, [@CR41], [@CR46]\], cell cycle control (miR-34a, -192, -215, -675) \[[@CR38]•, [@CR41], [@CR47]\], and migration, invasion, and metastasis (miR-126, -143, -196a, -200a, -200b, -200c, -373, -520c) \[[@CR38]•, [@CR41], [@CR44]\]. MiRNA pathway may also modulate DNA methylation (miR-143, -342) \[[@CR48], [@CR49]\].

In addition, miRNA alterations are correlated to a number of clinicopathologic features and outcomes related to CRC pathogenesis. MiR-21 is a representative example, since high levels of expression are associated with lymph node positivity, increased metastasis propensity and advanced tumor stages associated with worse overall survival \[[@CR50], [@CR51]\]. Additional miRNAs, including miR-17, -31, -125b, -126, -143, -196a, -200c, -320, -451, and -498, were identified as associated to an increase of metastasis potential, a decrease of disease-free survival, and a poor prognosis \[[@CR38]•, [@CR40]--[@CR42], [@CR44], [@CR46], [@CR52], [@CR53]\].

Several studies have identified miRNA expression signatures associated with MSS or MSI CRC phenotypes. These include miR-17, -92, -142, -146b, -212, -217, -510, -513, and -592 associated with MSS, whereas miR-20a, -101, -145, -432\*, -455, -484, -492, and -625 were higher in MSI-H tumors \[[@CR39], [@CR52], [@CR54]\]. Furthermore, four miRNAs (miR-31, -224, -552, and -592) were identified as able to discriminate between MMR-proficient and MMR-defective adenocarcinomas \[[@CR40]\].

All together, these data suggest that CRC-specific miRNA expression signatures are common events, which are representative of CRC-related genetic instability and may be a key event for tumor onset and development. Accordingly, miRNA expression signatures have great and valuable potential for diagnostic and prognostic purposes.

For the past decades, 5-fluorouracil (5-FU) has been and still is the most commonly used chemotherapeutic agent in CRC treatments. However, a significant fraction of patients are refractory or become resistant to 5-FU--based chemotherapies. A growing body of evidence is revealing the importance of miRNA alterations in the modulation of tumor response to 5-FU treatments. For instance, miR-92, -143, and -215, by impairing 5-FU--induced apoptosis \[[@CR55]\], could be implicated in the resistance to 5-FU developed by CRC patients presenting low level of expression of miR-92, -143, and -215 \[[@CR38]•, [@CR41]\]. In addition, miR-21, which plays a central role in colon cancer pathogenesis by targeting many TSGs with elevated expression in advanced tumor stages, was described as an independent predictive marker associated with poor survival and for which overexpression predicts a poor response to therapy \[[@CR50], [@CR51]\]. Finally, a recent study suggests that miRNA SNPs rs7372209 and rs1834306 in miR-26-a-1 and miR-100 genes, respectively, affect the clinical outcome of 5-FU--treated CRC patients \[[@CR56]\]. These data suggest that miRNA signatures have a potential as marker to predict chemotherapy response.

It has been suggested that, in addition to DNA hypermethylation-mediated silencing of miRNAs (Table [1](#Tab1){ref-type="table"}) \[[@CR45], [@CR53], [@CR57], [@CR58]••, [@CR59]--[@CR61]\], alterations of proteins involved in miRNA processing is observed in CRC. Indeed, Papachristou et al. \[[@CR62]\] reported that the nuclear ribonuclease Drosha and the cytoplasmic ribonucleases Dicer and Ago2 are possibly implicated in colorectal carcinogenesis and that Dicer could influence tumor progression to advanced stages.

Taken together, these findings demonstrate that miRNome alterations represent promising candidates to develop specific and sensitive biomarkers in CRC pathology with opportunities for primary to tertiary prevention levels.

Histones and Histone-Modifying Enzymes in CRC {#Sec6}
---------------------------------------------

An additional layer of epigenetic regulation of gene expression is represented by histone tail post-translational covalent modifications. Core histone (H2A, H2B, H3, H4) N-termini are modified by phosphorylation, acetylation, methylation, ubiquitylation, sumoylation, citrullination, β-N-acetylglucosamination, deimination, and ADP-ribosylation. Altogether, these dynamic and reversible modifications establish a "histone code" regulating chromatin structure and activity. The better understood modifications are acetylation of lysine and methylation of arginine and lysine residues. The acetylation/deacetylation reactions are catalyzed by histone acetyl transferases (HATs) and histone deacetylases (HDACs), respectively. Similarly, methylation/demethylation processes are driven by histone methyltransferase (HMTs) and histone demethylases (HDM). While acetylation occurs as a single addition, methylation exists at various levels on the same residue *(*ie, mono-, di-, and tri-methylation) \[[@CR63], [@CR64]\].

There is now clear evidence that aberrant histone modification profiles are closely connected to tumorigenesis. Indeed, dysregulated activity or expression of histone-modifying enzymes as well as their aberrant recruitment by cytogenetic alterations (eg, leukemia-associated fusion proteins) participate in cancer development by inducing aberrant regulation of oncogenes and/or TSGs, and affecting genome stability and/or chromosome segregation \[[@CR10], [@CR64], [@CR65]\]. Although our knowledge about histone code and histone-modifying enzymes is incomplete, some data suggest their implications in CRC. A study from Weichert et al. \[[@CR66]\] revealed that HDAC1, HDAC2, and HDAC3 are overexpressed in 36.4%, 57.9%, and 72.9% of CRC cases, respectively. Interestingly, the expression was significantly enhanced in strongly proliferating and poorly differentiated tumors. Thus, high HDAC expression levels are associated with reduced patient survival, with in addition, HDAC2 expression being a prognostic factor for survival \[[@CR66]\]. HDAC2 overexpression is accompanied by H4K12 and H3K18 acetylation and correlates with adenoma-carcinoma progression \[[@CR67]\]. HDAC1 increase was confirmed in another study reporting an upregulation of two HATs: K(lysine) acetyltransferase 2B (KAT2B, CBP) and p300. KAT2B overexpression was associated with long-term survival, whereas p300 overexpression was correlated with a poor prognosis \[[@CR68]\]. Interestingly, the class III HDAC sirtuin 1 is overexpressed in 37% of CRC patients and is mainly associated with MSI and CIMP-high phenotypes \[[@CR69]•\]. Finally, it was demonstrated that the expression of the cell-cycle regulator p21 is lower in CRC associated with widespread histone H3 hypo-acetylation in chromatin. These observations were connected to the development and progression of CRC but not with tumor biological behaviors \[[@CR70]\].

Dysregulation of enzymes involved in histone methylation is also observed in CRC. Indeed, the HMT suppressor of variegation 3--9 homolog 1 (SUV39H1) is overexpressed in 25% of CRC patients and its expression is significantly associated with DNMT1 expression \[[@CR36]\]. Furthermore, the histone H3 lysine 4-specific HMT suppressor of variegation, enhancer of zeste, and trithorax (SET)1 is over-expressed in colon tumor cells, where its expression promotes cell proliferation and survival \[[@CR71]\]. Moreover, the multiple myeloma SET domain (MMSET) HMT and putative oncoprotein is overexpressed in CRC patients with a worse 5-year survival. Recently, MMSET expression was associated with a good prognostic value in colon cancer and is more pronounced in early stages of colon carcinogenesis (dysplasia) than in adenocarcinomas \[[@CR72]\]. Noteworthy, the histone H3 lysine 9-specific HDM, Jumonji domain containing 1A (JMJD1A) was reported as a useful biomarker for hypoxic tumor cells \[[@CR73]\]. In humans, enhancer of zeste homolog 2 (EZH2) overexpression-mediated gene silencing has been identified in numerous tumor types associated with H3K27me3 widespread high levels in chromatin. Recent evidence demonstrated that EZH2 overexpression is a common feature of CRC (observed in 87% of cases) \[[@CR74]\]. Finally, it was suggested that oncogenic RAS pathways could modulate histone modifications to influence the expression of target genes involved in the regulation of cell proliferation \[[@CR75]\]. Accordingly, overexpression of the HMT SET and MYND domain-containing protein 3 (SMYD3) has been reported in mutated K-RAS CRC patients \[[@CR76]\].

Taken together these data suggest that histone modification profiles and histone-modifying enzymes could be used as marker as well as therapeutic/chemopreventive targets in CRC and therefore play a role in CRC prevention.

Chemoprevention, Epigenetics, and CRC {#Sec7}
=====================================

Epigenetic mechanisms by their potential reversibility represent interesting targets in CRC for chemopreventive approaches using dietary agents. Accumulating evidence suggests that natural molecules/nutrients present in our diet might modulate epigenetic events in humans. Table [2](#Tab2){ref-type="table"} summarizes compounds identified in various in vitro and in vivo tumor models that may exert their chemopreventive potential by targeting epigenetic mechanism(s). The current knowledge about some naturally occurring compounds, which may play a significant role in CRC chemoprevention related to epigenetic modulation, is discussed below.Table 2Compounds present in diet acting as epigenetic modulatorsDietary agentFood sourcePotential epigenetic target3,3′-diindolylmethaneBroccoli, cauliflower (indole-3-carbinol metabolite)Histone modifications, miRNAs6-methoxy-2E,9E-humuladien-8-oneGingerHistone modificationsAllicinGarlicHistone modificationsAllyl mercaptanGarlicHistone modificationsAnacardic acidCashew nutsHistone modificationsApigeninParsley, celeryDNA methylationBiochanin ASoyHistone modificationsButeinToxicodendron vernicifluumHistone modificationsButyrateGut flora--mediated fermentation of dietary fiberHistone modificationsCaffeic acidCoffeaHistone modificationsCatechinGreen teaHistone modificationsChlorogenic acidCoffeaHistone modificationsCinnamic acidCinnamonHistone modificationsCoumaric acidCinnamonHistone modificationsCurcumin (diferuloylmethane)TurmericHistone modifications, miRNAsDaidzeinSoyHistone modificationsDelphinidinCranberries, Concord grapes, pomegranatesHistone modificationsDiallyl disulfideGarlicHistone modificationsDihydrocoumarinSweet clover (Meliotus officinalis)Histone modifications(-)-Epigallocatechin gallateGreen teaDNA methylation, histone modifications, miRNAsEquolSoyHistone modificationsFisetinStrawberriesDNA methylationFlavoneMandarinHistone modificationsFolateLeafy vegetables, beans, peas, lentils, eggs, liverDNA methylation, histone modificationsGarcinol, isogarcinolGarcinia indicaHistone modificationsGenisteinSoybeanDNA methylation, histone modifications, miRNAsHesperidinCitrusDNA methylationIsoliquiritigeninLicoriceHistone modificationsIsothiocyanatesBroccoliHistone modifications, miRNAsKaempferolApples, nuts, tea, onionsHistone modificationsLuteolinCelery, parsleyHistone modificationsLycopeneTomatoes and various fruitsDNA methylationMCP30Bitter melonHistone modificationsMyricetinWalnuts and various berries, fruits, and vegetablesDNA methylationNaringeninCitrusDNA methylationPhloretinApplesDNA methylationPiceatannolGrapes (resveratrol metabolite)Histone modificationsPolyphenon BGreen and black teaHistone modificationsPomiferinMaclura pomiferaHistone modificationsProtocatechuric acidOlivesDNA methylationQuercetinApples, tea, onion, nuts, berriesDNA methylation, histone modificationsResveratrolGrapesHistone modificationsRosmarinic acidRosemaryDNA methylationS-allylmercaptocysteineGarlicHistone modificationsSanguinarineOpium poppyHistone modificationsSilibininMilk thistleHistone modificationsSinapinic acidSinapis (mustard)DNA methylationSulforaphaneBroccoliDNA methylation, histone modificationsSyringic acidRed grapesDNA methylationTheophyllineGreen and black teaHistone modificationsUrsolic acidBasilHistone modificationsSeleniumNuts, cereals, meat, fish, eggs, kidneyDNA methylation, histone modifications

Curcumin is well recognized for its chemopreventive and therapeutic properties in vitro and in vivo against many tumor types. Curcumin decreases inflammation cell proliferation, invasion, and angiogenesis, triggers apoptosis, and sensitizes tumor cells to cancer therapies \[[@CR77]--[@CR79]\]. These protective properties could be, at least partially, mediated by a modulation of epigenetic events. While no study was performed in colon cells, curcumin is a well-known inhibitor of p300/ KAT2B HAT activity \[[@CR80]\]. Furthermore, it was shown that curcumin modulates the miRNA pathway. Specifically, curcumin inhibits miR-21 expression via AP-1 leading to a decreased proliferation and metastasis potential in CRC \[[@CR81]\].

Butyrate is an essential short-chained fatty acid (SCFA) for the colon epithelia formed from bacteria-fermented dietary fibers. Butyrate triggers growth arrest, differentiation, and/or apoptosis in many in vitro and in vivo precancerous and tumor cell models including CRC cell lines \[[@CR82]--[@CR84]\]. These biological effects leading to carcinogenesis suppression have been proposed to account for the chemopreventive properties of butyrate and to be mediated by HDAC inhibition--induced histone hyperacetylation \[[@CR83], [@CR84]\]. Furthermore, butyrate was identified as the most potent HDAC inhibitor among various SCFAs tested in colon carcinoma cells. In the same study, cinnamic acid, coumaric acid, and caffeic acid also showed HDAC inhibitory activities \[[@CR85]\].

(-)-Epigallocatechin gallate (EGCG), the major polyphenol in green tea, has been extensively studied both in vitro and in animal models of carcinogenesis and is well recognized for its chemopreventive properties. EGCG seems to have DNA-demethylating properties since it can induce the reactivation of some methylation-silenced TSGs in various tumor models including human colon cancer cells, limiting their proliferation and invasiveness \[[@CR86], [@CR87]\].

Isothiocyanates such as sulforaphane (SFN) are sulfur phytonutrients abundant in broccoli reported to present chemopreventive properties in CRC. SFN has been initially found to inhibit in vitro HDAC activity in human colon cancer cells and then in numerous other models \[[@CR88], [@CR89]\]. In vivo, a study demonstrated that APCmin/+ mice with SFN-enriched diet have reduced tumor development associated with an increased histone acetylation and p21 expression \[[@CR90]\]. Remarkably, in humans, consumption of 68 g broccoli resulted in a significant inhibition of blood HDAC activity 3 h following intake \[[@CR91]\]. Furthermore, prolonged exposure to SFN induces a decrease of various class I and selected class II HDAC proteins and especially HDAC3 \[[@CR92]\].

3,3′-diindolylmethane (DIM) is a digestive metabolite of indole-3-carbinol, which is found in vegetables such as broccoli or cauliflower. DIM strongly decreases the expression of the anti-apoptotic protein survivin and enhances the effect of butyrate on both apoptosis in colon cancer cells and prevention of FAP in APCmin/+ mice. These effects were accompanied by a drastic decrease of HDAC1, HDAC2, and HDAC3 expression \[[@CR93]\], which could be explained by selective DIM-induced proteasomal degradation of class I HDACs (HDAC1--3, and 8), leading to p21 and p27 overexpression*.* These data may account for DIM's capability to trigger G2-cell cycle arrest and apoptosis \[[@CR94]\].

Garlic-derived sulfur compounds such as diallyl disulphide (DADS) or allyl mercaptan (AM) are known for their HDAC inhibitory potential. Thus, these compounds induce total histone hyperacetylation in colon cancer cells as well as CDKN1A promoter-associated histone hyperacetylation, which is responsible for p21 overexpression and correlated with a G2/M-cell cycle arrest \[[@CR89], [@CR95]\]. Remarkably, epidemiological data suggest that garlic consumption decreases risks of CRC. Thus, it is believed that the effect of these sulfur compounds on HDAC account for their anticarcinogenic and chemopreventive properties.

Quercetin has been shown to activate the class III HDAC sirtuin 1 (SIRT1) and to be a potent antitumor agent by decreasing proliferation, and triggering G2/M-cell cycle arrest and apoptosis in cancer cells \[[@CR96], [@CR97]\]. In addition, a study revealed that quercetin demethylates CDKN2A promoter in colon cells \[[@CR98]\]. Therefore, quercetin might present protective properties against CRC.

Finally, folate and selenium are common nutrients reported to influence epigenetic events. Epidemiological studies support the link between low folate concentrations and increased CRC risk \[[@CR99]\]. Folate is the main source of methyl group necessary for the production of SAM, a universal cofactor in methylation reactions. Thus, defects in folate metabolism or intake lead to hypomethylation of genomic DNA or proto-oncogene and alterations of histone methylation patterns associated with genomic instability in colon cells \[[@CR83]\]. Selenium has also been reported to alter epigenetic mechanisms, providing a rationale for its potential chemopreventive efficacy. Indeed, it was shown that colon DNA from rats fed a selenium-rich diet was hypomethylated, whereas low-selenium diet increases DNA methylation of the TSG von Hippel-Lindau \[[@CR100]\]. These data were linked to selenium propensity to inhibit DNMT1 activity and protein expression in colon cells \[[@CR101]\]. Furthermore, organoselenium metabolites of Se-methyl-L-selenocysteine and L-selenomethionine methylselenopyruvate induce HDAC inhibition--dependent histone H3 acetylation in colon cancer cells associated with an induction of p21 expression, which could account for G2/M cell cycle arrest and apoptosis \[[@CR102]\]. Therefore, unbalanced and improper consumption of these nutrients might have an injurious impact on colorectal carcinogenesis.

Conclusions and Perspectives {#Sec8}
============================

Since epigenetic alterations are reversible, they were initially considered as interesting targets for chemotherapy using DNMT and HDAC inhibitors such as 5-aza-2′-deoxycytidine (decitabine) and suberoylanilide hydroxamic acid (SAHA, vorinostat), respectively. These compounds induce pleiotropic biological effects including regulation of cell growth, differentiation, autophagy, senescence, and apoptosis. Additionally, they sensitize cells to classical chemotherapeutic agents and they mostly act synergistically as antitumor agents against cancer cells \[[@CR10], [@CR63], [@CR103], [@CR104]\]. Nonetheless, the use of such pharmacological epigenetic modulators is associated with some dose-limiting toxicities such as neutropenia and thrombocytopenia observed with SAHA or nonspecific cytotoxic effects observed with nucleoside analogues DNA demethylating agents inherent to their incorporation into DNA. In the perspective to reduce these drawbacks, natural compounds might represent a good alternative to identify safer epigenetic modulators. Accordingly, increasing evidence about the impact of environment on epigenetics as well as early occurrence of epimutations in carcinogenesis make us reconsider epigenetic events as promising preventive targets. However, to reach these attractive perspectives, we need to improve our current knowledge of CRC-associated early epigenetic changes, for early detection and to define promising epigenetic targets for chemoprevention. In addition, a clear impact of such chemopreventive strategies is needed, which requires a better rationale of studies to determine detail mechanisms, and assess safety and efficient doses for humans. Nevertheless, epigenetics and chemoprevention by dietary modulators is well associated with targeted therapy and personalized oncology and should ultimately aid to decrease CRC incidence and mortality rate.
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